Technical Analysis for PHGE - BiomX Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.50 | -2.57% | -0.01 |
PHGE closed down 12.18 percent on Wednesday, November 20, 2024, on 1.21 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | -2.57% | |
| Lower Bollinger Band Walk | Weakness | -2.57% | |
| New 52 Week Low | Weakness | -2.57% | |
| Wide Bands | Range Expansion | -2.57% | |
| Below Lower BB | Weakness | -2.57% | |
| Lower Bollinger Band Touch | Weakness | -2.57% | |
| Oversold Stochastic | Weakness | -2.57% | |
| Jack-in-the-Box Bearish | Bearish Swing Setup | -14.44% | |
| NR7 | Range Contraction | -14.44% | |
| Narrow Range Bar | Range Contraction | -14.44% |
| Alert | Time |
|---|---|
| Possible NR7 | about 3 hours ago |
| Down 5% | about 5 hours ago |
| Down 3% | about 5 hours ago |
| Down 2 % | about 5 hours ago |
| Fell Below Previous Day's Low | about 5 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/12/2024
BiomX Inc., a clinical-stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from dysbiosis of the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases, primary sclerosing cholangitis, and cancer. The company is based in Ness Ziona, Israel.
Sector: Industrials
Industry: Conglomerates
Keywords: Medicine Cancer Clinical Medicine Disease Autoimmune Disease Inflammatory Bowel Disease Chronic Disease Hepatology Digestive System Primary Sclerosing Cholangitis Bacteriophage
Classification
Sector: Industrials
Industry: Conglomerates
Keywords: Medicine Cancer Clinical Medicine Disease Autoimmune Disease Inflammatory Bowel Disease Chronic Disease Hepatology Digestive System Primary Sclerosing Cholangitis Bacteriophage
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.55 |
| 52 Week Low | 0.5041 |
| Average Volume | 85,793 |
| 200-Day Moving Average | 2.43 |
| 50-Day Moving Average | 0.89 |
| 20-Day Moving Average | 0.75 |
| 10-Day Moving Average | 0.69 |
| Average True Range | 0.09 |
| RSI (14) | 23.08 |
| ADX | 47.76 |
| +DI | 6.09 |
| -DI | 32.69 |
| Chandelier Exit (Long, 3 ATRs) | 0.74 |
| Chandelier Exit (Short, 3 ATRs) | 0.78 |
| Upper Bollinger Bands | 0.95 |
| Lower Bollinger Band | 0.54 |
| Percent B (%b) | -0.08 |
| BandWidth | 54.46 |
| MACD Line | -0.10 |
| MACD Signal Line | -0.08 |
| MACD Histogram | -0.0159 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.62 | ||||
| Resistance 3 (R3) | 0.63 | 0.61 | 0.60 | ||
| Resistance 2 (R2) | 0.61 | 0.58 | 0.60 | 0.60 | |
| Resistance 1 (R1) | 0.56 | 0.56 | 0.54 | 0.55 | 0.59 |
| Pivot Point | 0.53 | 0.53 | 0.52 | 0.53 | 0.53 |
| Support 1 (S1) | 0.48 | 0.50 | 0.47 | 0.47 | 0.43 |
| Support 2 (S2) | 0.46 | 0.48 | 0.45 | 0.42 | |
| Support 3 (S3) | 0.41 | 0.46 | 0.41 | ||
| Support 4 (S4) | 0.40 |
